Genta-Aventis Case Study: Failing Strategies Within Late Stage Vertical Licensing
| Format: | Electronisk Tidsskrift |
|---|---|
| Sprog: | engelsk |
| Udgivet: |
MarketLine, a Progressive Digital Media business
|
| Online adgang: | Full text available on EBSCOhost[Nov 2005-Nov 2005 |
Lignende værker
IDEC-Genentech Case Study: Successful Late Stage Licensing Strategies
Roche-Kosan Case Study: Successful Early Licensing Strategies
Forest Laboratories & Schering-Plough Case Studies: Pharmaceutical Licensing Strategies
Aventis SWOT Analysis
Sanofi-Aventis Case Study: Building a Successful Insulin Portfolio
Sanofi-Aventis SWOT Analysis
Licensing Loyalty
af: McLeod
af: McLeod
License to Play
af: Daliot-Bul
af: Daliot-Bul
License to Wed
af: Richman
af: Richman
Licensing Journal
Failing Families, Failing Science
af: Lincoln
af: Lincoln
Licensed Practical Nurse
Vertical Reefs
af: Wicksten
af: Wicksten
Lipitor Case Study: Lifecycle Management Strategies
Failed Frontiersmen
af: Donahue
af: Donahue
Words Fail
af: Dickinson
af: Dickinson
The Revolution that Failed
af: Fairclough
af: Fairclough
Failed Evidence
af: Harris
af: Harris
Failed Promises
af: Konisky
af: Konisky
IPO Exit Strategies Case Study: Undertaking a Successful IPO Exit Strategy
Staging Harmony
af: Brokaw
af: Brokaw
Staging Asia
af: Kuruppath
af: Kuruppath
Setting the Stage
af: Hays
af: Hays
Subversive Stages
af: Komporaly
af: Komporaly
Staging Revolution
af: Fan
af: Fan
Occupying the Stage
af: Bredeson
af: Bredeson
Staging Family
af: Mullenneaux
af: Mullenneaux
Staging the Amistad
af: Christensen
af: Christensen
On Stage Alone
af: Gitelman
af: Gitelman
Staging Ghana
af: Schauert
af: Schauert
Stage for Action
af: Dail
af: Dail
The Stages of Memory
af: Young
af: Young
Lignende værker
- IDEC-Genentech Case Study: Successful Late Stage Licensing Strategies
- Roche-Kosan Case Study: Successful Early Licensing Strategies
- Forest Laboratories & Schering-Plough Case Studies: Pharmaceutical Licensing Strategies
- Aventis SWOT Analysis
- Sanofi-Aventis Case Study: Building a Successful Insulin Portfolio